True LD - Search Results

1

Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning-Assisted Gland Analysis.

Xie W, Reder NP, Koyuncu C, Leo P, Hawley S, Huang H, Mao C, Postupna N, Kang S, Serafin R, Gao G, Han Q, Bishop KW, Barner LA, Fu P, Wright JL, Keene CD, Vaughan JC, Janowczyk A, Glaser AK, Madabhushi A, True LD, Liu JTC. Xie W, et al. Among authors: true ld. Cancer Res. 2022 Jan 15;82(2):334-345. doi: 10.1158/0008-5472.CAN-21-2843. Epub 2021 Dec 1. Cancer Res. 2022. PMID: 34853071 Free PMC article.

2

Surgical pathology examination of the prostate gland. Practice survey by American society of clinical pathologists.

True LD. True LD. Am J Clin Pathol. 1994 Nov;102(5):572-9. doi: 10.1093/ajcp/102.5.572. Am J Clin Pathol. 1994. PMID: 7942619

3

Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma.

Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, Liu AY, Hood L. Nelson PS, et al. Among authors: true ld. Cancer Res. 1998 Jan 15;58(2):232-6. Cancer Res. 1998. PMID: 9443398

4

Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.

Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH. Ellis WJ, et al. Among authors: true ld. Clin Cancer Res. 1996 Jun;2(6):1039-48. Clin Cancer Res. 1996. PMID: 9816265

5

Expression profiling reveals hepsin overexpression in prostate cancer.

Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Magee JA, et al. Cancer Res. 2001 Aug 1;61(15):5692-6. Cancer Res. 2001. PMID: 11479199

6

Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases.

Roudier MP, Corey E, True LD, Hiagno CS, Ott SM, Vessell RL. Roudier MP, et al. Among authors: true ld. Cancer Treat Res. 2004;118:311-39. doi: 10.1007/978-1-4419-9129-4_13. Cancer Treat Res. 2004. PMID: 15043198 Review. No abstract available.

7

Metastases of prostate cancer express estrogen receptor-beta.

Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Lai JS, et al. Among authors: true ld. Urology. 2004 Oct;64(4):814-20. doi: 10.1016/j.urology.2004.05.036. Urology. 2004. PMID: 15491740

8

Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma.

Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, Coleman I, Nelson PS. Moore S, et al. Among authors: true ld. Int J Cancer. 2005 Apr 20;114(4):563-71. doi: 10.1002/ijc.20773. Int J Cancer. 2005. PMID: 15609334 Free article.

9

Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence.

Etzioni R, Hawley S, Billheimer D, True LD, Knudsen B. Etzioni R, et al. Among authors: true ld. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1040-6. doi: 10.1158/1055-9965.EPI-04-0584. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15894650

10

I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.

Herstein A, Wallner K, Merrick G, Mitsuyama H, Armstrong J, True L, Cavanagh W, Butler W. Herstein A, et al. Cancer J. 2005 Sep-Oct;11(5):385-9. doi: 10.1097/00130404-200509000-00005. Cancer J. 2005. PMID: 16259869 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

329 results

Search Page